Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Acromegaly is a chronic disease of adulthood resulting from excessive secretion of growth hormone (GH) and the subsequent elevation of insulin-like growth factor-I (IGF-I).1 It is usually caused by a benign tumour in the anterior pituitary gland.2
Acromegaly is equally prevalent in men and women, with a worldwide estimate of 60 cases per million,3 although more recent studies have estimated this number to be higher,4 and an annual incidence of 3-4 cases per million.
The mean age of diagnosis is 41–48 years,5 and diagnosis takes an average of 8 years from onset of symptoms.6 If left untreated or unsuccessfully treated, acromegaly is associated with increased mortality and risk of metabolic and cardiovascular complications;1 the mortality rate for patients with uncontrolled acromegaly is approximately 2–3 times higher than that of the general population.7
Acromegaly affects virtually all organs and tissues, causing metabolic, cardiovascular, neurological and musculoskeletal morbidities.7 The clinical signs can result from chronic exposure to the effects of GH and IGF-I and/or a secondary effect of the mass of the tumour.8
To find out more about ACRODAT, supporting your patients or to order starter kits
Learn more about Somavert reimbursement in your area and how to arrange funding
Learn more about how Somavert can help your acromegaly patients
** This is an optional area where footnotes can live.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020